Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Biosimilar Trends Report

- PMLiVE

Amgen gets prevention claim for cholesterol drug Repatha

FDA approves new labelling on heart attack and stroke risk reduction

- PMLiVE

Mylan gets first biosimilar Herceptin OK from FDA

Ogivri approved by US regulators for all of Roche blockbuster's indications

- PMLiVE

First Herceptin biosimilar cleared in Europe

Ontruzant is approved for all the same indications as Roche’s blockbuster

Amgen appoints Wanda Austin to its Board

She will also serve as a member of the firm's audit committee

- PMLiVE

Amgen hopes its latest Kyprolis trial hits the mark with regulators

A.R.R.O.W study takes aim at once-weekly dosing regimen in multiple myeloma

Sanofi reception

US court lifts ban on sales of Sanofi’s Praluent

The duo can continue to compete against Amgen's rival PCSK9 Repatha

- PMLiVE

Amgen pledges $1.5bn for CytomX preclinical cancer drugs

Stellar valuations for immuno-oncology candidates continue

- PMLiVE

AbbVie deal with Amgen sets biosimilar Humira launch dates

Agreement will see Europe access the drug over four years earlier than patients in the US

- PMLiVE

Amgen’s Mvasi is first FDA-approved cancer biosimilar

Offers prospect of lower-cost alternative to Roche's Avastin

Biosimilars: what the future looks like

Biosimilars: what the future looks like

- PMLiVE

Roche faces prospect of second Rituxan biosimilar in US

FDA begins its review of Sandoz's version of the immunotherapy treatment

- PMLiVE

Amgen signs real world study and mobile data partnership

Will work with health and wellbeing group Humana on risk prevention

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links